Niemann-Pick type A disease is a lysosomal storage disorder caused by a deficiency in acid sphingomyelinase (ASM) activity. Previously we showed that storage pathology in the ASM knockout (ASMKO) mouse brain can be corrected by adeno-associated virus serotype 2 (AAV2)-mediated gene transfer. The present experiment compared the relative therapeutic efficacy of different recombinant AAV serotype vectors (1, 2, 5, 7, and 8) using histological, biochemical, and behavioral endpoints. In addition, we evaluated the use of the deep cerebellar nuclei (DCN) as a site for injection to facilitate global distribution of the viral vector and enzyme. Seven-week-old ASM knockout mice were injected within the DCN with different AAV serotype vectors encoding human ASM (hASM) and then killed at either 14 or 20 weeks of age. Results showed that AAV1 was superior to serotypes 2, 5, 7, and 8 in its relative ability to express hASM, alleviate storage accumulation, and correct behavioral deficits. Expression of hASM was found not only within the DCN, but also throughout the cerebellum, brainstem, midbrain, and spinal cord. This finding demonstrates that targeting the DCN is an effective approach for achieving widespread enzyme distribution throughout the CNS. Our results support the continued development of AAV based vectors for gene therapy of the CNS manifestations in Niemann-Pick type A disease.
N
iemann-Pick type A disease (NPA) is a lysosomal storage disorder caused by a deficiency in acid sphingomyelinase (ASM) activity. Loss of ASM activity results in lysosomal sphingomyelin (SPM) accumulation, secondary metabolic defects such as aberrant cholesterol metabolism, and subsequently the loss of cellular function in various organ systems including the central nervous system (CNS) (1, 2) . Previously, we demonstrated that intracerebral delivery of adeno-associated virus serotype-2 encoding human ASM (AAV2-hASM) is effective in correcting lysosomal storage pathology in ASM knockout (ASMKO) mice (3) . Interestingly, correction of lysosomal storage pathology not only occurred at the injection site (i.e., hippocampus), but also in regions (e.g., entorhinal cortex) that send and͞or receive input from the injection site. This finding, in accordance with previous work (4) , demonstrated that neuronal circuits can be used to achieve AAV vector and protein distribution via axonal transport to regions that are proximal or distal to the injection site.
Despite our initial success with AAV2, investigation of the relative therapeutic efficacy of additional serotypes is warranted. Serotype-dependent variations in cellular tropism, rates of diffusion, and transduction efficiencies may translate into disparate levels of therapeutic efficacy (5, 6) . Furthermore, we wish to show that AAV-mediated hASM expression prevents disease initiated neurodegeneration (i.e., Purkinje cell loss) and disturbances in motor function in ASMKO mice (7, §).
To examine the relative ability of different AAV serotype vectors encoding hASM to prevent Purkinje cell loss and improve functional outcome in ASMKO mice, we targeted the deep cerebellar nuclei (DCN). In addition to being highly connected with the cerebellar cortex (i.e., major terminal projection site of Purkinje cells), the DCN is also connected with a number of central sites including the pons, medulla, and spinal cord (9) (10) (11) (12) (13) . We anticipate that targeting the DCN with AAV vectors capable of axonal transport will result in widespread enzyme distribution throughout the cerebellum and possibly additional regions of the CNS. This result is desirable particularly for the treatment of global neurometabolic disorders such as NPA disease.
Therefore, the present experiments evaluated the relative therapeutic efficacy of recombinant AAV serotype vectors 1, 2, 5, 7, and 8 encoding hASM to express enzyme, alleviate storage pathology, rescue Purkinje cells, and correct behavioral deficits in ASMKO mice. Our results show that targeting the DCN is a viable strategy for achieving widely distributed enzyme expression and that AAV serotype 1 is superior to serotypes 2, 5, 7, and 8 at multiple levels of analysis.
Materials and Methods
Animals. Male homozygous (Ϫ͞Ϫ) ASMKO mice (n ϭ 66) and male wild-type (n ϭ 16) littermate controls were bred from heterozygote matings (ϩ͞Ϫ). Animals were housed under a 12 h͞12 h light͞dark cycle and provided with food and water ad libitum. All procedures were performed under a protocol approved by the Institutional Animal Care and Use Committee.
Stereotaxic Surgery. After being anesthetized with isoflurane, mice (Ϸ7 weeks of age) were unilaterally injected into the DCN (anteriorposterior, Ϫ5.75 from bregma; mediolateral, Ϫ1.8 from bregma; dorsoventral, Ϫ2.6 from dura; incisor bar, 0.0) with one of the following AAV serotype vectors (n ϭ 8 per vector): AAV1-␤gal (control), AAV1-hASM, AAV2-hASM, AAV5-hASM, AAV7-hASM, and AAV8-hASM. Vectors were delivered with a 10-l Hamilton syringe at a rate of 0.5 l͞min for a total of 1.86 ϫ 10 10 genome copies per injection site. The final injection volume for each vector was 4 l per site. One hour before and 24 h after surgery, mice were given ketoprofen (5 mg͞kg s.c.) for analgesia.
Production of Serotype-Specific Recombinant AAV-hASM. The fulllength human ASM cDNA under the control of the human CMV immediate-early promoter, with a simian virus 40 polyadenylation sequence and a hybrid intron, was cloned into a plasmid containing inverted terminal repeats (ITRs) from AAV serotype 2 (AAV2 ITR) (14) . Hybrid vectors were produced by triple transfection using a series of helper plasmids containing serotype specific capsid coding domains in addition to the AAV type 2 replication genes. This strategy allowed for the packaging of AAV2 ITR vectors into each serotype-specific virion (15) . With this approach the hASM recombinant genome was used to generate a series of rAAV-hASM vectors of various serotypes including AAV1, 2, 5, 7, and 8. Recombinant AAV vectors were purified by ion-exchange chromatography (serotypes 1, 2, and 5) (16) or CsCl centrifugation (serotypes 7 and 8) (15) . Purified vector was stored in PBS buffer with 10% glycerol. To minimize aggregation, all vector preparations were kept at a final vector concentration of 5.0 ϫ 10 12 DNase-resistant particles (DRPs) per ml. The final titer of AAV-hASM virion particles (DRPs), was determined by TaqMan PCR of the CMV sequence (17) . Infectious titer assay was performed as described in Clark et al. (17) . The particle infectious unit ratios of serotypes 1, 2, and 5 were in the range 100-400, whereas the particle infectious unit ratio infectious of serotypes 7 and 8 were 3,000. All vector preparations were negative for both bioburden and endotoxin.
Death and Tissue Processing. Mice that were unilaterally injected with different AAV serotypes encoding for hASM were killed 7 weeks after injection (14 weeks of age) with euthasol (150 mg͞kg i.p.) and then either decapitated (n ϭ 5 per group) or transcardially perfused (n ϭ 3 per group) with fixative as described (18) . Brains from decapitated mice were rapidly removed, snapfrozen in liquid nitrogen, dissected into three sections [right cerebral hemisphere, left cerebral hemisphere, and cerebellum (including the brainstem)], homogenized, and analyzed for hASM by ELISA (18) . Cerebral sections included underlying structures as well. Fifty-micrometer Vibratome sections of brains and spinal cords from perfused mice were processed for hASM expression, cholesterol accumulation with filipin staining, and Purkinje cell survival with calbindin staining as described (3, 18) . Sections stained with filipin were evaluated for the percent reduction in fluorescent deposits using a METAMORPH Image Analysis System (Universal Imaging, Downington, PA) as described (18) . A second cohort of ASMKO mice received bilateral injections (4 l per site) aimed at the DCN to determine whether increasing hASM distribution within the cerebellum leads to further improvement in rotarod performance. ASMKO mice that received bilateral injections of AAV1-␤gal (n ϭ 8), AAV1-hASM (n ϭ 5), and AAV2-hASM (n ϭ 5) were killed at 14 weeks after injection (20 weeks of age). Brains were snap-frozen in liquid nitrogen, bisected at midline, and then divided into five sections (S1, S2, S3, S4, and S5) by using a mouse brain matrix (ASI Instruments). Sections 1-4 were Ϸ2 mm apart from each other, with S1 being the most rostral and S5 the most caudal. Section 5 contained the cerebellum (i.e., injection site) and brainstem. The right hemisphere was used to quantify brain SPM levels (19) and the left hemisphere was used to determine hASM levels (18) .
Calbindin Staining and Purkinje Cell Counts. Brains were processed for immunofluorescence by using primary antibodies directed against calcium binding protein (calbindin). Sections were washed with potassium phosphate buffer (KPB) and then rinsed with potassium PBS (KPBS). Sections were then blocked in 5% donkey serum͞0.25% Triton X-100 in KPBS for up to 3 h and then incubated in 5% donkey serum͞0.2% Triton X-100͞1:2,500 mouse anti-calbindin (Sigma) in KPBS. After 72 h at 4°C, sections were rinsed three times with KPBS containing 0.1% Triton X-100. A secondary antibody, donkey anti-mouse CY3 (1:333, Jackson ImmunoResearch) in KPBS containing 0.1% Triton X-100 was added and incubated for 90 min at room temperature. Sections were washed with KPB and then mounted onto gel-coated slides. Calbindin-positive cells were visualized under epifluorescence. To quantify Purkinje cells of the cerebellum, four full-faced, medial plane cerebellar sections were selected from each animal. Calbindin-immunopositive Purkinje cells were viewed under a fluorescent microscope and cell bodies were counted at a magnification of ϫ20. Each lobe was counted separately. Two separate focal planes were counted per lobe. Only cells with a cell body in focus were counted to ensure that no cells were counted twice. There was no noticeable difference in cell size between ASMKO and wild-type mice (calbindin staining was limited to healthy cells and not cells with high levels of storage pathology).
Rotarod Testing. Each mouse was tested by accelerating and rocking rotarod for motor function on the Smartrod (AccuScan) using an established protocol (19) . Mice that received unilateral injection of AAV-hASM were tested at 7 weeks after treatment (14 weeks of age), whereas mice that received bilateral injections were tested 14 weeks after treatment (20 weeks of age).
Statistics. Latency to fall off the rotarod, hASM protein levels, and SPM levels were analyzed with separate one-way ANOVAs. Follow-up analyses were conducted with Dunnett's post hoc test where appropriate. All values were considered significant at P Ͻ 0.05.
Results
Distribution of hASM in AAV-Injected ASMKO Mouse Brain. Positive hASM immunostaining was observed throughout the cerebellum ( Fig. 1) , pons, medulla, and spinal cord (Table 1 and Fig. 2 ) after unilateral intracerebellar injection of different AAV serotype vectors encoding hASM. It should be noted that variations in hASM staining within different brain regions was relatively consistent among mice from different experimental groups. However, in such a small animal, it is inevitable that the exact site of injection within the DCN varied between animals and, therefore, influenced the pattern of hASM expression between different treatment groups. Nevertheless, within the cerebellum, mice treated with AAV serotype 1 had the most widespread (i.e., spread between lobules within the same sagittal section) distribution of hASM staining, whereas mice treated with the serotype 2 vector had the most restricted distribution of hASM protein staining. hASM distribution in mice treated with serotypes 5, 7, and 8 vectors was intermediate between these two groups. Medial-lateral spread between sagittal sections was maximal in mice treated with AAV serotypes 1 and 8 and minimal in mice injected with the serotype 2 vector. Serotypes 5 and 7 vectors initiated medial-lateral spread patterns that were intermediate between AAV serotypes 1 and 2. Positive hASM staining was detected within each layer of the cerebellar cortex (i.e., molecular, Purkinje, and granular) for all serotypes. However, the AAV2 vector transduced mainly granular neurons, whereas serotype vectors 7 and 8 transduced largely cells in the molecular layer. AAV1 and -5 vectors transduced primarily Purkinje cells (Fig. 6 , which is published as supporting information on the PNAS web site).
Quantitative analysis of hASM expression by ELISA in cerebellar tissue homogenates supported the immunohistochemical findings. Mice injected with serotypes 1 and 8 vectors demonstrated significantly (P Ͻ 0.0001) higher cerebellar hASM levels when compared to all other mice (Fig. 3) . This finding is in agreement with the serotype 1 and 8 vectors having the most pervasive medial-lateral spread of positive hASM staining. Cerebellar hASM tissue homogenate levels from mice injected with serotypes 2, 5, and 7 vectors were not above background levels. The level of AAV-mediated hASM expression (as de-tected by ELISA) in mice that received bilateral injections was again significantly higher (P Ͻ 0.001) in mice treated with serotype 1 than serotype 2 (data not shown).
Reduction of Cholesterol Accumulation. An absence or deficiency of functional ASM protein results in lysosomal accumulation of sphingomyelin, and subsequent secondary metabolic defects such as abnormal cholesterol accumulation (7, 20) . Cholesterol buildup in the ASMKO mouse brain can be visualized by using filipin, an autofluorescent molecule isolated from Streptomyces filipinensis. Wild-type mouse brains do not stain positively with filipin. In all AAV-hASM-treated ASMKO mice, clearance of filipin staining (Table 2 and Figs. 7 and 8, which are published as supporting information on the PNAS web site) overlapped with areas that were positive for hASM immunostaining, indicating that each serotype vector was capable of generating a functional transgene product. As previously demonstrated (3, 18) , cholesterol clearance also occurred in areas anatomically connected with the injection site that did not stain positively for hASM. METAMORPH analysis indicated that a reduction in filipin staining occurred throughout the entire rostral-caudal axis. These results indicate that the level of hASM required to correct cholesterol storage pathology in the ASMKO mouse brain is minimal (i.e., below the limit of detection of hASM immunofluorescence). In the cerebellum and brainstem, cholesterol was maximally reduced in mice treated with AAV serotypes 1 and 8, whereas in the diencephalon and cerebral cortex mice injected with serotype 8 had the best overall level of filipin clearance. Reduction in SPM Accumulation. A lack of hASM enzymatic activity leads to accumulation of its primary substrate, SPM. Mice that were bilaterally injected with AAV serotype 1 or 2 vectors were assayed for SPM levels. A significant (P Ͻ 0.01) reduction in SPM levels in the cerebellum (i.e., injection site) was observed in mice treated with both serotype 1 and 2 vectors (Fig. 4) . SPM tissue content levels were also significantly reduced in sections 2, 3, and 4 (each section being 2 mm apart from the next) in mice injected with AAV1, but not in mice treated with the serotype 2 vector. This finding corroborates the notion that serotype 1 is superior to AAV2 in its relative ability to reduce storage accumulation in ASMKO mice.
Calbindin-Positive Cells in the Purkinje Cell Layer. The ASMKO mouse cerebellum undergoes progressive loss of Purkinje cells up to 20 weeks of age. Between 7 and 9 weeks, the majority (up to 90%) of Purkinje cells in the anterior lobules of ASMKO mouse cerebellum have died off, and this is correlated with the onset of impaired motor function (7, §). Calbindin is a widely accepted Purkinje cell marker. Our results indicate that AAVmediated hASM expression in the ASMKO mouse cerebellum partially prevents the loss of calbindin-positive cells in the Purkinje cell layer ( Table 3) . As expected, there were very few calbindin-positive cells in the Purkinje cell layer for lobules I-III (mice were injected at 7 weeks of age). Calbindin-positive cell counts in the Purkinje cell layer for lobules IV͞V were significantly higher in mice treated with AAV1-hASM vs. control mice. A significantly higher number of calbindin-positive cells in the Purkinje layer was also observed in lobule VII for mice treated with serotype 5 and in lobule VIII for mice treated with serotypes 2 and 5. In lobules IX and X, there were no significant differences between wild-type and ASMKO mice (or between AAVhASM-treated mice) in calbindin-positive cell counts in the Purkinje cell layer. This finding was expected, because at 14 weeks of age (i.e., age at death), Purkinje cells in these lobules are still viable in ASMKO mice. Across all lobules, calbindinpositive cell counts in the Purkinje cell layer were highest in mice treated with AAV serotypes 1, 2, and 5 and lowest in mice treated with AAV serotypes 7 and 8.
Improvement in Motor Coordination͞Behavioral Function.
On the accelerating rotarod test mice unilaterally injected with AAV serotypes 1 and 8 demonstrated a significantly (P Ͻ 0.01) longer latency to fall than control mice (ASMKO mice treated with AAV1-␤gal) (Fig. 5A ). For the rocking rotarod test, only mice injected with AAV1 demonstrated a significantly (P Ͻ 0.01) longer latency to fall than control mice (Fig. 5B) . A second cohort of mice received bilateral injections aimed at the DCN to determine whether increasing enzyme distribution leads to further improvement in rotarod performance. ASMKO mice that received bilateral injection of either serotype 1 or 2 vectors performed significantly (P Ͻ 0.01) better than control mice in both the accelerating and rocking tests ( Fig. 5 C and D) .
Discussion
Several studies have shown that AAV-mediated gene transfer corrects neuropathology and, to a lesser extent, behavioral deficits in mouse models of neurometabolic disease (21) (22) (23) (24) (25) (26) (27) . However, experiments in various lysosomal storage disease mouse models (e.g., mucopolysaccharidosis VII, infantile neuronal ceroid lipofuscinosis, and Sanfilippo type IIIB disease) have been primarily restricted to AAV serotypes 1 and 2 to mediate gene transfer in the brain. Recently, we have shown that AAV2 is also effective in initiating gene transfer and correcting the lysosomal storage pathology in the ASMKO mouse brain (3). In our current study, we examined the use of the DCN as a site for widespread distribution of enzyme and the efficacy of different AAV serotype (i.e., 1, 2, 5, 7, and 8) vectors in ASMKO mice using a variety of histological, biochemical, and behavioral criteria. Our results indicated that AAV serotype 1 is superior to serotypes 2, 5, 7, and 8 in its relative ability to initiate enzyme expression, correct storage pathology in the brain and improve motor functional outcome. Moreover, we also showed that targeting the DCN with viral vectors capable of axonal transport can be exploited to maximize enzyme (i.e., ASM) expression throughout the CNS. Disease-compromised neurons can support the transport of virus and͞or enzyme to regions distal to the site of injection (3, 4) . In our current experiments, histological processing was optimized for detection of hASM protein rather than mRNA. Therefore, it is difficult to determine definitively (as a function of serotype) what extent of hASM staining (and therefore, subsequent substrate reduction) is due to vector transport during the initial gene delivery to the DCN vs. hASM protein transport from the DCN. Nevertheless, here we demonstrate that unilateral delivery of AAV- Percent reduction in filipin (i.e., cholesterol) staining (as compared to ASMKO mice  injected with AAV1-␤gal) for selected brain regions in ASMKO mice (14 weeks of age) . 4 . Mean Ϯ SEM brain SPM levels (at 20 weeks of age) in ASMKO (bilaterally injected with AAV1-␤gal) and ASMKO mice bilaterally treated with AAV serotypes 1 and 2 (n ϭ 6 per group) encoding hASM. Brains were divided into five rostrocaudal sections (S1, most rostral; S5, most caudal). The asterisk indicates significantly different from ASMKO mice (P Ͻ 0.01).
hASM to the DCN resulted in positive hASM immunostaining throughout the cerebellum, as well as in the pons, medulla, and spinal cord. An absence of positive hASM staining in regions (e.g., ventrolateral thalamus) with direct connections to the DCN that did have correction of storage pathology indicates that the level of hASM that underwent transport to these regions was, in some instances, below the limit of immunohistochemical detection. Nonetheless, our findings indicate that targeting the DCN can be used to maximize delivery of virus and͞or enzyme throughout the CNS. This targeting approach may prove to be useful in treating lysosomal storage diseases that involve global neuropathology such as NPA disease, particularly if this mode of axon-mediated therapy is applied to humans, where the brain size is huge compared to the mouse. The cellular tropism and transduction efficiencies for a number of different AAV serotypes have been examined in a variety of animal models of neurological disease (28) . For example, it has been reported that the transduction efficiency of serotype 1 and 5 is superior to AAV2 in the murine brain (29) . Studies completed in both rats (6) and cats (30) demonstrated that the transduction efficiency for serotype 1 exceeds both serotypes 2 and 5. Our results support and extend these previous findings. AAV1 initiated the most widespread and highest level of hASM expression, whereas mice injected with the serotype 2 vector had the most limited spread pattern and lowest level of hASM expression when compared to mice treated with serotypes 5, 7, and 8. Overall, our histological and biochemical findings indicate that AAV serotype 1 is superior to serotypes 2, 5, 7, and 8 in its relative ability to initiate and spread hASM expression throughout the CNS.
One way to determine the functional activity of AAV expressed hASM within the ASMKO CNS is to assess its influence on cholesterol storage pathology, a secondary metabolic defect in NPA disease. We have shown that a reduction in cholesterol storage pathology is positively correlated with a decrease in SPM accumulation (3, 18) . In all AAV-hASM-treated mice, correction of cholesterol storage pathology overlapped with areas (e.g., cerebellum, pons, and medulla) that were positive for hASM immunostaining, indicating that each serotype vector generated a functional enzyme. As previously demonstrated (3), correction of abnormal cholesterol metabolism also occurred in distal areas that did not stain positively for hASM (e.g., thalamus), suggesting that the levels of hASM required for correction of cholesterol storage pathology is low. Analysis of SPM (primary metabolic defect in NPA) provides a more direct measurement of hASM enzyme activity. Indeed, ASMKO mice that received bilateral intracerebellar injections of serotypes 1 and 2 encoding hASM showed a significant reduction in SPM storage within the cerebellum. As observed with cholesterol accumulation, a significant reduction in SPM storage also occurred in regions outside the cerebellum in ASMKO mice bilaterally treated with serotype 1, but not with serotype 2. Overall, our findings indicate that AAV serotype 1 is superior to serotypes 2, 5, 7, and 8 in reducing lysosomal storage accumulation in the CNS of ASMKO mice.
Quantification of calbindin-positive cells in the Purkinje cell layer provided yet another test for determining the efficacy of AAV generated hASM. Factors that may account for the ability of a given AAV serotype to increase the number of counted calbindin-positive cells in the Purkinje cell layer include (i) distribution of hASM expression; (ii) level of hASM expression; (iii) age of mice at time of vector delivery; and (iv) the lag period between viral transduction and enzyme expression. A significantly higher number of counted calbindin expressing Purkinje cells in lobules IV͞V in mice treated with AAV1-hASM was consistent with both our immunohistochemical (i.e., spread of hASM within the cerebellum) and quantitative (i.e., level of hASM) results. Although expression kinetics of the different AAV serotypes have not been investigated in the ASMKO Table 3 . Calbindin-positive cell counts in the Purkinje cell layer of cerebellar lobules I-X in wild-type and ASMKO (14 weeks of age) after unilateral intracerebellar injection of different AAV serotypes (1, 2, 5, 7, and 8; n ‫؍‬ 3 Numbers shown in bold are significantly different from ASMKO mice (i.e., mice treated with AAV-␤gal); P Ͻ 0.01. mouse brain, previous experiments completed in ASMKO mouse liver indicate that AAV1-and -8-mediated hASM expression was maximal within 1 week, whereas peak AAV2-mediated hASM expression was not reached until after 3 weeks (31). The age of mice at the time of treatment will also likely have a significant influence on the relative ability of a given serotype to prevent loss of the Purkinje cell phenotype. For example, it was expected that very few calbindin-positive cells would be counted in the anterior lobules (i.e., I-III), because the majority of these cells had already died by 8 weeks of age (7, §). Therefore, serotypes that failed to save cells with the Purkinje cell phenotype may prove to be efficacious when delivered bilaterally (to increase overall protein distribution), at higher titers, and at earlier time points (i.e., injection age Ͻ7 weeks). With respect to possible future therapy in humans, it would seem desirable to initiate therapy as early as possible to prevent cell death, although treatment at later times is likely to have a very positive effect of halting disease progression. Purkinje cell death in the ASMKO mouse is negatively correlated with rotarod behavioral performance. ASMKO mouse rotarod performance begins to decline significantly (as compared to wild-type mice) at 10 weeks of age. § Consistent with our histochemical and biochemical results, AAV1-hASMtreated mice demonstrated a significant improvement on the rotarod behavioral test. Mice treated with AAV8-hASM also performed significantly better than control ASMKO mice treated with AAV1-␤gal. It is difficult to speculate why mice treated with AAV8-hASM demonstrated significant improvement on the accelerating rotarod test despite the observation that these mice had limited Purkinje cell survival. Perhaps both the distribution and level of hASM expression (as compared to serotypes 2,5 and 7) initiated by AAV8 promoted the survival of additional cell types within the cerebellum that collectively play a significant role in modulating motor coordination. Another possible explanation is that mice treated with serotype 8 had correction of extra-CNS storage pathology (i.e., within the musculature). The supposition is supported by evidence suggesting that AAV8 is capable of crossing the blood-brain barrier (8) . Whether the serotype 8 vector traversed the blood-brain barrier into systemic circulation after being injected into the brain is unknown. Future experiments will need to examine the ability of serotype 8 to improve motor performance after systemic administration. For the rocking (alternating) rotarod test, only mice treated with AAV1-hASM performed significantly better than mice injected with AAV1-␤gal. Poor performance on the rocking rotarod may be due to the nature of the test, which requires coordinated alternating movements; it is important to note that, in this experiment, only one side of the brain was treated. Indeed, bilateral injection of AAV1-hASM led to further improvement on both the rocking and accelerating tests. Interestingly, mice that were bilaterally injected with AAV2-hASM (a vector that did not initiate improvement in rotarod performance when unilaterally injected) also demonstrated a significant improvement on both rotarod tests, but not to same extent as mice treated with AAV1. These results indicate that enzyme distribution may be a critical parameter for initiating improvement in coordinated motor tasks in mouse models of neurometabolic disease.
In conclusion, our results demonstrated that AAV-mediated expression of hASM not only alleviated storage accumulation, but also impaired neurodegeneration and improved functional outcome in ASMKO mice. Overall, a positive relationship was observed between the level of AAV expressed hASM, enzyme distribution, extent of storage pathology, number of calbindinpositive cells in the Purkinje cell layer, and rotarod behavioral performance.
